Canaccord Genuity Reiterates a 'Buy' on Pernix Therapeutics (PTX); Solid Q4, Execution & Business Development The Focus
Tweet
Share
E-mailGet Alerts PTX Hot Sheet
Price: $0.21 --0%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Pernix Therapeutics (NYSE: PTX) price target of $15.00.
Analyst, Randall Stanicky, said, "PTX reported a clean quarter that was consistent with the pre-announced range that came with the business update in early March. The path from here we think will be linked to execution across several fronts including: (1) effective launch of new “GI product” in May leaves potential for it to be a leading portfolio product; (2) ability to grow scripts for CEDAX and NATROBA (new nationwide Point-of-Sale coupon) where focus is high; and importantly (3) business development productivity which has been active and we see no slowdown. Bottom line: risk/reward remains favorable with the 44% 3-year EPS CAGR most robust across our coverage and holding potential to move higher should we see more deal activity."
For an analyst ratings summary and ratings history on Pernix Therapeutics click here. For more ratings news on Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $9.48 yesterday.
Analyst, Randall Stanicky, said, "PTX reported a clean quarter that was consistent with the pre-announced range that came with the business update in early March. The path from here we think will be linked to execution across several fronts including: (1) effective launch of new “GI product” in May leaves potential for it to be a leading portfolio product; (2) ability to grow scripts for CEDAX and NATROBA (new nationwide Point-of-Sale coupon) where focus is high; and importantly (3) business development productivity which has been active and we see no slowdown. Bottom line: risk/reward remains favorable with the 44% 3-year EPS CAGR most robust across our coverage and holding potential to move higher should we see more deal activity."
For an analyst ratings summary and ratings history on Pernix Therapeutics click here. For more ratings news on Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $9.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
